Sam Barker, Ph.D., was elected to the AtheroGenics board of directors in July 2006. Dr. Barker also serves on the Governance and Nominating Committee and the Compensation Committee of the Board. He is one of three co-founders of Clearview Projects, Inc., a multi-disciplinary advisory firm specializing in strategic thinking, corporate development transactions, product alliances, product strategy/development and executive management, with a focus on the global healthcare sector. Dr. Barker worked at Bristol-Myers Squibb for over 30 years in Research and Development, Manufacturing, Business Development, Sales and Marketing, and General Management. After the merger of Bristol-Myers and Squibb in 1989, he held several executive positions including Vice President, Asia/Pacific for the Pharmaceutical Group; President, Intercontinental, Bristol-Myers Squibb Company; and President, U.S. Pharmaceuticals Group before retiring in May 1999. He served as President and CEO of Clearview Projects from 2003-2004. Dr. Barker has been the Chairman of the Board of Lexicon Genetics, Inc., since March 2005 and serves on the Board of Directors of UCB, US and Cadence Pharmaceuticals, Inc. in San Diego, California. He is an Advisor to Symphony Capital, a private equity partnership. He is a member of the Board of Trustees, the Cancer Institute of New Jersey. Dr. Barker received a B.S. from Henderson State College, and holds graduate degrees from the University of Arkansas and Purdue University. |